Comparison between 3-nitrooxyphenyl acetylsalicylate (NO-ASA) and O 2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1, 2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 2, 2010, Pages 443-450

  Chattopadhyay, Mitali ^a   Velazquez, Carlos A ^b   Pruski, April ^a   Nia, Kamran V ^a   Abdellatif, Khaled R ^b   Keefer, Larry K ^c   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTIPYRETIC ANALGESIC AGENT; CARRAGEENAN; CVM 01; MALONALDEHYDE; NITRIC OXIDE; O 2 (ACETYLSALICYLOXYMETHYL) 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; PROSTAGLANDIN E2; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; FEVER; HYPERALGESIA; LIPID PEROXIDATION; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; STOMACH HEMORRHAGE; STOMACH MUCOSA LESION; STOMACH ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ANTIPYRETICS; ASPIRIN; DINOPROSTONE; DISEASE MODELS, ANIMAL; EDEMA; FEVER; GASTRIC MUCOSA; HYDRAZINES; HYPERALGESIA; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MOLECULAR STRUCTURE; PRODRUGS; RATS; RATS, WISTAR; STOMACH ULCER; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78149253685     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.171017     Document Type: Article

References (39)

1. Aalykke C and Lauritsen K (2001) Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15:705-722.
2. Anand BS, Romero JJ, Sanduja SK, and Lichtenberger LM (1999) Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94:1818-1822.
3. Best R, Lewis DA, and Nasser N (1984) The anti-ulcerogenic activity of the unripe plantain banana (Musa species). Br J Pharmacol 82:107-116.
4. Brown JF, Hanson PJ, and Whittle BJ (1992) Nitric oxide donors increase mucus gel thickness in rat stomach. Eur J Pharmacol 223:103-104.
5. Brown JF, Keates AC, Hanson PJ, and Whittle BJ (1993) Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am J Physiol 265:G418-G422.
6. Chan AT, Ogino S, and Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142.
7. Cryer B and Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. American Journal of Medicine 104:413-421.
8. Davies KM, Wink DA, Saavedra JE, and Keefer LK (2001) Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution. J Am Chem Soc 123:5473-5481.
9. Fiorucci S and Del Soldato P (2003) NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 35 (Suppl 2):S9-S19.
10. Fiorucci S, Santucci L, and Distrutti E (2007) NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 39:1043-1051.
11. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, and Morelli A (2003) Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124:600-607.
12. FitzGerald GA (2003) COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2:879-890.
13. Flossmann E, Rothwell PM, and British Doctors Aspirin Trial and the UK-TIA Aspirin Trial (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-1613.
14. Jaksch W, Dejaco C, and Schirmer M (2008) 4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int 28:1187-1195.
15. Kato S, Suzuki K, Ukawa H, Komoike Y, and Takeuchi K (2001) Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. Dig Dis Sci 46:1690-1699.
16. Kurinets A and Lichtenberger LM (1998) Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats. Dig Dis Sci 43:786-790.
17. Li-yuan J, Li C, and Yi-hua Z (2004) Improved synthesis of 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester. Chin J Med Chem 14:178-179.
18. Lichtenberger LM, Romero JJ, de Ruijter WM, Behbod F, Darling R, Ashraf AQ, and Sanduja SK (2001) Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J Pharmacol Exp Ther 298:279-287.
19. Martin GR and Wallace JL (2006) Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) 231:130-137.
20. Orido T, Fujino H, Hasegawa Y, Toyomura K, Kawashima T, and Murayama T (2008) Indomethacin decreases arachidonic acid uptake in HCA-7 human colon cancer cells. J Pharmacol Sci 108:389-392.
21. Pinto L, Borreli F, Bomberdelli E, Cristonic A, and Capasso F (1998) Antiinflammatory, analgesis and antipyretic effects of glaucine in rats and mice. Pharm Pharmacol Commun 4:502-505.
22. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C, Schou M, and Curnow KM (2006) Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 185:501-506.
23. Scheiman JM and Fendrick AM (2007) Summing the risk of NSAID therapy. Lancet 369:1580-1581.
24. Spitz GA, Furtado CM, Sola-Penna M, and Zancan P (2009) Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem Pharmacol 77:46-53.
25. Stanek A, Gadowska-Cicha A, Gawron K, Wielkoszyński T, Adamek B, Cieślar G, Wiczkowski A, and Sieroń A (2008) Role of nitric oxide in physiology and pathology of the gastrointestinal tract. Mini Rev Med Chem 8:1549-1560.
26. Stefano F and Distrutti E (2007) Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current status. Curr Top Med Chem 7:277-282.
27. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, and Zandi PP (2008) NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70:17-24.
28. Velázquez C, Praveen Rao PN, and Knaus EE (2005) Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem 48:4061-4067.
29. Velázquez CA, Chen QH, Citro ML, Keefer LK, and Knaus EE (2008) Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem 51:1954-1961.
30. Velázquez CA, Praveen Rao PN, Citro ML, Keefer LK, and Knaus EE (2007) O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies. Bioorg Med Chem 15:4767-4774.
31. Vlad SC, Miller DR, Kowall NW, and Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70:1672-1677.
32. Wallace JL (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88:1547-1565.
33. Wallace JL, Caliendo G, Santagada V, Cirino G, and Fiorucci S (2007) Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 132:261-271.
34. Wallace JL, Chapman K, and McKnight W (1999) Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 126:1200-1204.
35. Wallace JL, Reuter BK, and Cirino G (1994) Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a novel approach for reducing gastrointestinal toxicity. J Gastroenterol Hepatol 9 (Suppl 1):S40-S44.
36. Wallace JL and Vong L (2008) NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Curr Opin Investig Drugs 9:1151-1156.
37. Winter CA, Risley EA, and Nuss GW (1962) Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 111:544-547.
38. Yasuda O, Takemura Y, Kawamoto H, and Rakugi H (2008) Aspirin: recent developments. Cell Mol Life Sci 65:354-358.
39. Zhao J, Qi R, Li R, Wu W, Gao X, Bao L, and Lu S (2008) Protective effects of aspirin against oxidized LDL-induced inflammatory protein expression in human endothelial cells. J Cardiovasc Pharmacol 51:32-37.